|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16,and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women显示文摘 | Block SL Nolan T Sattler C | 2006 | Pediatrics2006，118，5： | 1 |
| 2 | Clinical trial and post- licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18 )virus-like panicle vaccine 显示文摘 | Block SL Brown DR Chatterjee A | 2009 | Pediatr Infect Dis J2009，29，2： | 1 |
| 3 | The immu- nogenicity and safety of a quadrivalent live attenuated influenza vaccine in children显示文摘 | BLOCK SL FALLOON J HIRSCHFIELD JA | 2012 | Pediatr Inject Dis J2012，，： | 1 |
| 4 | A randomized, double- blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults显示文摘 | BLOCK SL YI T SHELDON E | 2011 | Vaccine2011，29，50： | 1 |
| 5 | Five-day twice daily cefdinir therapy for acut otitis media:Microbiologic and clinicl efficacy显示文摘 | Block SL Hedrick JA Kratzer J | 2000 | Pediat infect dis j2000，19，12： | 1 |
| 6 | Safety and immu-nogenicity of a 13-valent pneumococcal conjugate vaccine显示文摘 | Bryant KA Block SL Baker SA | 2010 | Pediatrics2010，125，5： | 1 |
| 7 | amoxicillin/clavulanate for treatment of suppurative acut otitis media in children显示文摘 | Block SL McCarty JM Hedrick JA | 2000 | Pediat infect dis j2000，19，12： | 1 |
| 8 | Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6,11,16,18 L1 vires-like partiele vaccine in preadolescents andadolescents:a randomized controlled trial显示文摘 | Reisinger KS Block SL Lazcano-Ponce E | 2007 | Pediatr Infect Dis J2007，26，3： | 1 |
| 9 | Adenoviral mediated herpes simplex virus thymidine kinase gene transfer:Regression of hepatic metastasis of pancreatic tumors显示文摘 | Chen SH Kosai KI Finegold M Woo SL | 1997 | Pancreas1997，15，1： | 1 |
| 10 | Safety, tolerability and im- munofenicity of a formalin-inactivated hepatitis A vaccine (VAQ- TA) in rural Kentucky children显示文摘 | Block SL Hedrick JA Tyler RD | 1993 | Pediatr Infect Dis J1993，12，12： | 1 |
| 11 | Efficacy and safety of SBR759, a new iron-based phosphate binder显示文摘 | Block GA Brillhart SL Persky MS | 2010 | Kidney Int2010，77，10： | 1 |
| 12 | Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media显示文摘 | Block SL | 1997 | Pediatr Infect Dis J1997，16，： | 1 |
| 13 | A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study显示文摘 | Block SL Cifaldi M Gu Y | 2005 | Clin Ther2005，27，6： | 1 |
| 14 | Efficacy and safety of SBR759, a new iron-based phosphate binder 显示文摘 | Block G A Brillhart SL Persky MS | 2010 | Kidney Int2010，77，： | 1 |
| 15 | Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6,11,16,18 L1 virus-like particle vaccine in preadolescents and adolescents:a randomized controlled trial显示文摘 | Reisinger KS Block SL Lazcano-Ponce E | 2007 | Pediatr Infect Dis J2007，26，： | 1 |
| 16 | Increasing bacterial resis-tancein pediatric acute conjunctivitis(1997-1998) 显示文摘 | Block SL Hedrick J Tyler R | 2000 | AmimicrobAgents Chemother2000，44，： | 1 |
| 17 | Clinical trial and postlicensure safety profile of a prophylactic human papillomavirus (types 6,11,16,and 18) 11 virus-like particle vaccine显示文摘 | Block SL Brown DR Chatterjee A | 2010 | Pediatr Infect Dis J2010，29，： | 1 |
| 18 | Efficacy, immuno- genicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life 显示文摘 | Block SL Vesikari T Boveia MG | 2007 | Pediatrics2007，119，1： | 1 |
| 19 | A comparison of 5 days of therapy with eefdinir or azithromyein in children with a- cute otitis media: amuhicenter, prospective, single-blind study 显示文摘 | Block SL Cifaldim Gu Y | 2005 | Clin Wher2005，27，6： | 1 |
| 20 | Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media显示文摘 | Casey JR Block SL Hedrick J | 2012 | Drugs2012，72，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员